Medpace Holdings, Inc. (NASDAQ:MEDP) Holdings Boosted by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 92.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,939 shares of the company's stock after buying an additional 38,427 shares during the period. BNP Paribas Financial Markets owned about 0.26% of Medpace worth $26,684,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MEDP. Quantbot Technologies LP increased its position in shares of Medpace by 87.8% during the third quarter. Quantbot Technologies LP now owns 12,604 shares of the company's stock worth $4,207,000 after purchasing an additional 5,892 shares in the last quarter. FMR LLC increased its position in Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company's stock worth $77,114,000 after buying an additional 24,362 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Medpace by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 21,469 shares of the company's stock valued at $7,166,000 after buying an additional 340 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Medpace by 42.6% in the third quarter. Bank of Montreal Can now owns 5,874 shares of the company's stock valued at $1,947,000 after acquiring an additional 1,755 shares during the period. Finally, Loomis Sayles & Co. L P grew its position in shares of Medpace by 7.2% during the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company's stock worth $68,696,000 after acquiring an additional 13,880 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. William Blair reiterated an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Robert W. Baird upped their price objective on Medpace from $349.00 to $354.00 and gave the company a "neutral" rating in a research note on Monday, November 25th. Truist Financial lowered their target price on Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Finally, TD Cowen cut their price target on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Medpace has a consensus rating of "Hold" and a consensus price target of $380.56.

Medpace Stock Up 0.5 %

MEDP stock traded up $1.67 on Friday, reaching $340.63. 214,814 shares of the company's stock were exchanged, compared to its average volume of 284,415. The stock has a fifty day moving average of $337.82 and a 200-day moving average of $371.22. Medpace Holdings, Inc. has a twelve month low of $268.80 and a twelve month high of $459.77. The firm has a market cap of $10.59 billion, a PE ratio of 29.83, a P/E/G ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the company earned $2.22 earnings per share. The business's quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.